이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

2014년 10월 24일 업데이트: Bristol-Myers Squibb

A Multi-center, Randomized, Double-Blind, Two-Arm, Phase III Study in Patients With Untreated Stage III (Unresectable) or IV Melanoma Receiving Dacarbazine Plus 10 mg/kg Ipilimumab (MDX-010) vs. Dacarbazine With Placebo

The purpose of this clinical research study is to examine the safety and effectiveness (how well the drug works) of two different treatments for patients with melanoma. One treatment is an investigational compound (a drug that is not currently approved by the United States Food and Drug Administration [FDA]), know as Ipilimumab (also known as MDX-010 or BMS-734016) together with an approved chemotherapy drug called Dacarbazine

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

For the extension phase:

Allocation: single arm study; Masking: open label; Intervention Model: Single Group

연구 유형

중재적

등록 (실제)

681

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

  • 남아프리카
      • Johannesburg, 남아프리카, 2199
        • Local Institution
    • Eastern Cape
      • Port Elizabeth, Eastern Cape, 남아프리카, 6000
        • Local Institution
    • Gauteng
      • Groenkloof, Gauteng, 남아프리카, 0181
        • Local Institution
      • Pretoria, Gauteng, 남아프리카, 0041
        • Local Institution
      • Saxonworld, Gauteng, 남아프리카, 2196
        • Local Institution
    • Western Cape
      • Cape Town, Western Cape, 남아프리카, 7570
        • Local Institution
  • 네덜란드
      • Eindhoven, 네덜란드, 5623 EJ
        • Local Institution
      • Hv Amsterdam, 네덜란드, 1081
        • Local Institution
      • Wurzburg, 네덜란드, 97080
        • Local Institution
  • 노르웨이
    • Oslo
      • Montebello, Oslo, 노르웨이, 0310
        • Local Institution
  • 독일
      • Berlin, 독일, 12200
        • Local Institution
      • Heidelberg, 독일, 69120
        • Local Institution
      • Jena, 독일, 07740
        • Local Institution
      • Kiel, 독일, 24105
        • Local Institution
      • Mannheim, 독일, 68167
        • Local Institution
      • Muenchen, 독일, 81675
        • Local Institution
      • Tubingen, 독일, 72076
        • Local Institution
  • 러시아 연방
      • Moscow, 러시아 연방, 115478
        • Local Institution
      • Moscow, 러시아 연방, 105229
        • Local Institution
      • Murmansk, 러시아 연방, 183047
        • Local Institution
      • Ryazan, 러시아 연방, 390011
        • Local Institution
      • Samara, 러시아 연방, 443066
        • Local Institution
      • St Petersburg, 러시아 연방, 198255
        • Local Institution
      • St.-Petersburg, 러시아 연방, 191104
        • Local Institution
      • Stavropol, 러시아 연방, 355047
        • Local Institution
    • Stavropol
      • Pyatigorsk, Stavropol, 러시아 연방, 357502
        • Local Institution
  • 미국
    • California
      • Anaheim, California, 미국, 92801
        • Pacific Cancer Medical Center
      • La Verne, California, 미국, 91750
        • Wilshire Oncology Medical Group Inc
      • Los Angeles, California, 미국, 90025
        • The Angeles Clinic and Research Institute
      • Palm Springs, California, 미국, 92262
        • Comprehensive Cancer Center
      • San Diego, California, 미국, 92123
        • Sharp Clinical Oncology Research
    • Connecticut
      • Hartford, Connecticut, 미국, 06105
        • Saint Francis Hospital and Medical Center
      • Stamford, Connecticut, 미국, 06902-3628
        • Hematology Oncology, P.C.
    • Florida
      • Jacksonville, Florida, 미국, 32256
        • Cancer Specialists Of North Florida Beaches
      • Orlando, Florida, 미국, 32806
        • Orlando Health, Inc. M.D. Anderson Cancer Center Orlando
      • Port Saint Lucie, Florida, 미국, 34952
        • Hematology Oncology Associates of the Treasure Coast
    • Illinois
      • Chicago, Illinois, 미국, 60637
        • University of Chicago
      • Normal, Illinois, 미국, 61761
        • Mid-Illinois Hematology/Oncology Associates, Ltd.
      • Park Ridge, Illinois, 미국, 60068
        • Oncology Specialists, SC
    • Indiana
      • Fishers, Indiana, 미국, 46037
        • Central Indiana Cancer Centers
      • Indianapolis, Indiana, 미국, 46202
        • Indiana University Cancer Center
    • Kansas
      • Hutchinson, Kansas, 미국, 67502
        • Hutchinson Clinic, Pa
    • Kentucky
      • Hazard, Kentucky, 미국, 41701
        • Kentucky Cancer Clinic
    • Maryland
      • Baltimore, Maryland, 미국, 21215
        • Sinai Hospital of Baltimore
      • Baltimore, Maryland, 미국, 21204
        • Greater Baltimore Medical Center
    • Massachusetts
      • Boston, Massachusetts, 미국, 02115
        • Dana Farber Cancer Institute
    • Missouri
      • Columbia, Missouri, 미국, 65203
        • Ellis Fischel Cancer Center
      • Saint Joseph, Missouri, 미국, 64507
        • St Joseph Oncology Inc
    • New Mexico
      • Albuquerque, New Mexico, 미국, 87106
        • University of New Mexico Cancer Center
    • New York
      • New York, New York, 미국, 10065
        • Memorial Sloan Kettering Cancer Center
    • North Carolina
      • Charlotte, North Carolina, 미국, 28204
        • Blumenthal Cancer Center
    • Oregon
      • Portland, Oregon, 미국, 97213
        • Providence Portland Medical Center
    • Pennsylvania
      • Bethlehem, Pennsylvania, 미국, 18015
        • St. Luke's Hospital & Health Network
    • South Carolina
      • Mount Pleasant, South Carolina, 미국, 29464
        • Lowcountry Hematology & Oncology, Pa
    • Tennessee
      • Knoxville, Tennessee, 미국, 37916
        • Thompson Cancer Survival Center
      • Nashville, Tennessee, 미국, 37232
        • Vanderbilt-Ingram Cancer Ctr
    • Texas
      • Lubbock, Texas, 미국, 79410
        • Joe Arrington Cancer Research and Treatment Center
    • Virginia
      • Richmond, Virginia, 미국, 23226
        • Virginia Cancer Institute
  • 벨기에
      • Brasschaat, 벨기에, 2930
        • Local Institution
      • Brussels, 벨기에, 1200
        • Local Institution
      • Edegem, 벨기에, B-2650
        • Local Institution
      • Gent, 벨기에, 9000
        • Local Institution
  • 브라질
      • Sao Paulo, 브라질, 01508-010
        • Local Institution
    • Ceara
      • Fortaleza, Ceara, 브라질, 60430-230
        • Local Institution
    • Rio Grande Do Sul
      • Porto Alegre, Rio Grande Do Sul, 브라질, 90050-170
        • Local Institution
      • Porto Alegre, Rs, Rio Grande Do Sul, 브라질, 90610-000
        • Local Institution
  • 스위스
      • Basel, 스위스, CH-4031
        • Local Institution
      • Geneva, 스위스, 1211
        • Local Institution
  • 스페인
      • Barcelona, 스페인, 08036
        • Local Institution
      • Canarias, 스페인, 38320
        • Local Institution
      • Valencia, 스페인, 46014
        • Local Institution
      • Zaragoza, 스페인, 50009
        • Local Institution
  • 아르헨티나
      • Buenos Aires, 아르헨티나, C1426ANZ
        • Local Institution
      • Buenos Aires, 아르헨티나, C1408INH
        • Local Institution
      • Buenos Aires, 아르헨티나, 1185
        • Local Institution
      • Cordoba, 아르헨티나, X5000AAI
        • Local Institution
      • Santa Fe, 아르헨티나, S3000FFU
        • Local Institution
  • 아일랜드
      • Cork, 아일랜드
        • Local Institution
      • Galway, 아일랜드
        • Local Institution
    • Dublin 4
      • Dublin, Dublin 4, 아일랜드
        • Local Institution
  • 영국
    • Avon
      • Bristol, Avon, 영국, BS2 8ED
        • Local Institution
    • Dorset
      • Poole, Dorset, 영국, BH15 2JB
        • Local Institution
    • Essex
      • Chelmsford, Essex, 영국, CM1 7ET
        • Local Institution
    • Greater London
      • London, Greater London, 영국, SW3 6JJ
        • Local Institution
    • Merseyside
      • Wirral, Merseyside, 영국, CH63 3JY
        • Local Institution
    • Surrey
      • Guildford, Surrey, 영국, GU2 7XX
        • Local Institution
  • 오스트리아
      • Vienna, 오스트리아, 1090
        • Local Institution
  • 우크라이나
      • Cherkassy, 우크라이나, 18009
        • Local Institution
      • Dnepropetrovsk, 우크라이나, 49044
        • Local Institution
      • Lviv, 우크라이나, 79031
        • Local Institution
      • Uzhgorod, 우크라이나, 88000
        • Local Institution
  • 이스라엘
      • Jerusalem, 이스라엘, 91120
        • Local Institution
      • Tel Aviv, 이스라엘, 64239
        • Local Institution
  • 이탈리아
      • Genova, 이탈리아, 16128
        • Local Institution
      • Milano, 이탈리아, 20141
        • Local Institution
      • Napoli, 이탈리아, 80131
        • Local Institution
      • Padova, 이탈리아, 35128
        • Local Institution
      • Ragusa, 이탈리아, 97100
        • Local Institution
      • Rome, 이탈리아, 00144
        • Local Institution
      • Siena, 이탈리아, 53100
        • Local Institution
  • 체코 공화국
      • Olomouc, 체코 공화국, 775 20
        • Local Institution
      • Praha, 체코 공화국, 128 08
        • Local Institution
  • 칠레
      • Santiago, 칠레
        • Local Institution
  • 캐나다
    • Alberta
      • Edmonton, Alberta, 캐나다, T6G 1Z2
        • Local Institution
    • Quebec
      • Montreal, Quebec, 캐나다, H3T 1E2
        • Local Institution
      • Montreal, Quebec, 캐나다, H1T 2W4
        • Local Institution
    • Saskatchewan
      • Saskatoon, Saskatchewan, 캐나다, S7N 4H4
        • Local Institution
  • 포르투갈
      • Lisboa, 포르투갈, 1099-023
        • Local Institution
  • 폴란드
      • Gdansk, 폴란드, 80-219
        • Local Institution
      • Lodz, 폴란드, 93-509
        • Local Institution
      • Lublin, 폴란드, 20-090
        • Local Institution
      • Poznan, 폴란드, 61-866
        • Local Institution
      • Wroclaw, 폴란드, 51-124
        • Local Institution
  • 프랑스
      • Bordeaux, 프랑스, 33075
        • Local Institution
      • Marseille, 프랑스, 13009
        • Local Institution
      • Paris, 프랑스, 75010
        • Local Institution
      • Pierre Benite, 프랑스, 69495
        • Local Institution
      • Villejuif, 프랑스, 94805
        • Local Institution
    • Cedex
      • Brest, Cedex, 프랑스, 29200
        • Local Institution
    • Cedex 1
      • Nantes, Cedex 1, 프랑스, 44093
        • Local Institution
    • Cedex 2
      • Saint Etienne, Cedex 2, 프랑스, 42055
        • Local Institution
  • 헝가리
      • Kaposyar, 헝가리, 7400
        • Local Institution
  • 호주
    • New South Wales
      • Coffs Harbour, New South Wales, 호주, 2450
        • Local Institution
      • Newcastle, New South Wales, 호주, 2300
        • Local Institution
      • Port Macquarie, New South Wales, 호주, 2444
        • Local Institution
    • Queensland
      • South Brisbane, Queensland, 호주, 4101
        • Local Institution
    • Victoria
      • Box Hill, Victoria, 호주, 3128
        • Local Institution

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Informed Consent
  • Measurable Disease
  • Eastern Cooperative Oncology Group (ECOG) 0 or 1
  • Lab / imaging requirements
  • Neg for Human Immunodeficiency Virus (HIV), Hepatitis B (HepB), C
  • Men and Women > 18 years (16 were allowable)
  • Prior therapy restriction (adjuvant only)

Exclusion:

  • Pregnant / nursing
  • Inadequate contraception
  • Brain metastasis
  • Primary ocular or mucosal melanoma

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm A: Ipilimumab and Dacarbazine
In Maintenance phase: Ipilimumab will be continued. Dacarbazine was given up to Week 22 and is not given in the Maintenance phase
의약품: Ipilimumab

Intravenous solution; intravenous; 10mg/kg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24, until disease progression, unacceptable toxicity or withdrawal of consent

In Maintenance phase: Only Ipilimumab: 10mg/kg, every 12 weeks will be continued until disease progression

다른 이름들:
  • BMS-734016
  • MDX-010
의약품: Dacarbazine
Intravenous solution; intravenous; 850 mg/m^2; one dose every 3 weeks for 22 weeks, until disease progression, unacceptable toxicity or withdrawal of consent
활성 비교기: Arm B: Placebo and Dacarbazine
의약품: Dacarbazine
Intravenous solution; intravenous; 850 mg/m^2; one dose every 3 weeks for 22 weeks, until disease progression, unacceptable toxicity or withdrawal of consent
의약품: Placebo
Intravenous solution; intravenous; 0 mg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24; until disease progression, unacceptable toxicity or withdrawal of consent

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Overall Survival (OS)
기간: Date of randomization to 37 months through 5-year follow-up and up to approximately 76 months
OS was defined as the time from the date of randomization until the date of death. Analysis of OS was to be done once 416 deaths had occurred (primary endpoint). However, analysis occurred at 414 deaths (February 7, 2011), due to operational timing of the study. Median number of months of OS and associated confidence interval calculated using the method of Brookmeyer and Crowley.
Date of randomization to 37 months through 5-year follow-up and up to approximately 76 months

2차 결과 측정

결과 측정
측정값 설명
기간
Survival Rate at 1 Year, 18 Months, 2 Years, and 3 Years
기간: Date of randomization to 3 years following randomization
The survival rate (percentage of participants alive) was defined as the probability that a participant is alive at 1 year (or 18 months, 2 years, or 3 years) following randomization and was estimated via the Kaplan-Meier method.
Date of randomization to 3 years following randomization
Disease Control Rate (DCR)
기간: First dose to last tumor assessment prior to subsequent therapy at data cutoff for Primary Endpoint (approximately 5 years)
DCR=number whose best overall response (BOR) was partial response (PR), complete response (CR) or stable disease (SD), divided by all randomized participants (unevaluable participants included). Independent review committee assessment. BOR=date of first dose to last tumor assessment prior to subsequent cancer therapy (including tumor resection, excluding palliative local radiotherapy). Modified World Health Organization criteria: CR=disappearance of all lesions; no evidence of progressive disease (PD); PR=50% or more decrease in the sum of products of the longest diameter and greatest perpendicular diameter of all index lesions compared with baseline; SD=neither sufficient decrease to qualify for PR nor sufficient increase to qualify for PD; PD=at least 25% increase in sum of products of all index lesions and/or appearance of any new lesions; nonindex lesions: appearance of any new lesions and/or unequivocal progression of nonindex lesions.
First dose to last tumor assessment prior to subsequent therapy at data cutoff for Primary Endpoint (approximately 5 years)
Median Number of Months of Progression-free Survival (PFS)
기간: Randomization to date of progression or death to approximately 5 years
PFS=time between randomization and date of progression or death, whichever occurs first. Participants who died without reported prior progression were considered to have progressed on date of death. For those alive and not progressed, PFS was censored on date of last evaluable tumor assessment (TA). Those who have not died and have no recorded postbaseline TA were censored at randomization. Those who died without any recorded postbaseline TA were considered to have progressed on date of death. Evaluation was conducted by both investigator and an independent review committee (IRC), who assessed radiologic imaging studies, photographs of skin lesions, and clinical data. Progressive disease defined using modified criteria of the World Health Organization: demonstration of at least a 25% increase in the sum of products of all index lesions or the appearance of any new lesions. For nonindex lesions: appearance of any new lesions or unequivocal progression of nonindex lesions.
Randomization to date of progression or death to approximately 5 years
Progression-free Survival (PFS) Rate Truncated at Week 12
기간: Day 78
PFS rate=probability patient was progression-free at Day 78, calculated as total patients receiving treatment and with an overall response of stable disease (SD), partial response (PR), or complete response (CR) at Week 12, divided by total patients. For those alive and not progressed at or before Week 12, PFS censored on date of last evaluable tumor assessment (TA) at or before Week 12. Those with an assessment of PD prior to Week 12 and subsequent assessment of SD, PR, or CR at Week 12 were called progression-free at Week 12. Those with no recorded postbaseline TA dated on or before Day 109, and who had not died on or before Day 109, were censored at randomization. PD=at least 25% increase in sum of products of all index lesions or appearance of any new lesions. Both an investigator and independent review committee (IRC) assessed radiologic imaging studies, photographs of skin lesions, and clinical data. IRC assessment was considered primary over that of the investigators.
Day 78
Best Overall Response Rate (BORR)
기간: First dose to last tumor assessment at data cutoff for primary endpoint (approximately 5 years)
BORR=number with Best Overall Response (BOR) of complete response (CR) or partial response (PR), divided by total number of randomized patients. BOR=date of first dose to the last tumor assessment prior to subsequent cancer therapy (including tumor resection surgery but excluding palliative local radiotherapy for bone lesions). Independent review committee assessment. Modified criteria of the World Health Organization (mWHO): CR=disappearance of all lesions; no evidence of progressive disease; PR=50% or greater decrease in the sum of products of the longest diameter and greatest perpendicular diameter of all index lesions compared with baseline. Immune-related (ir) response criteria (irRC) assess tumor response in patients on immunotherapy: irCR=disappearance of all lesions in 2 consecutive observations at least 4 weeks apart; irPR=50% or greater decrease in total measureable tumor burden compared with peak in 2 observations at least 4 weeks apart.
First dose to last tumor assessment at data cutoff for primary endpoint (approximately 5 years)
Duration of Response (DOR): Randomized Participants With Response of Complete Response (CR) or Partial Response (PR)
기간: Day of CR or PR to day of PD or death up to data cutoff for primary endpoint (approximately 5 years)
DOR defined in those with Best Overall Response (BOR)=CR or PR per independent review committee (IRC) as time between date of response of confirmed CR or PR, whichever occurred first, and date of PD or death. If PR assessed before CR, DOR confirmed at earlier time-point showing PR. Modified criteria of the World Health Organization (mWHO): CR=disappearance of all lesions;no evidence of PD; PR=50% or greater decrease in the sum of products of longest and greatest perpendicular diameters (SPD) of all index lesions compared with baseline. PD=an increase of 25% or greater in SPD of index lesions compared with the smallest recorded sum, or appearance of 1 or more new lesions. Immune-related response criteria (irRC): SD=50% decrease in total measurable tumor burden compared with peak cannot be established nor 25% increase compared with nadir, in absence of unequivocal progression of nonindex lesions. Unconfirmed immune-related (ir) CR, irPR, or irPD=irSD.
Day of CR or PR to day of PD or death up to data cutoff for primary endpoint (approximately 5 years)
Time to Response: All Randomized Participants With Response to Treatment
기간: First dose to date of BOR up to data cutoff for primary endpoint (approximately 5 years)
Time to response was defined as the time between the first dose of study therapy and the date when measurement criteria were met for Best Overall Response (BOR) of partial response (PR) or complete response (CR), whichever occurred first, per independent review committee. Note that if an overall response of PR occurred before confirmation of CR, the time to response endpoint was not determined by the time that the BOR of CR was shown but rather by the earlier time point showing PR. Modified criteria of the World Health Organization: CR=disappearance of all lesions; no evidence of progressive disease (PD); PR=50% or more decrease in the sum of products of the longest and greatest perpendicular diameters (SPD) of all index lesions compared with baseline; PD=an increase of 25% or greater in the SPD of index lesions compared with the smallest recorded sum, or the appearance of 1 or more new lesions.
First dose to date of BOR up to data cutoff for primary endpoint (approximately 5 years)
Duration of Stable Disease (SD): Randomized Participants With Stable Disease
기간: Week 12 to date of disease progression or death up to data cutoff for primary endpoint (approximately 5 years)
Duration of SD was defined in those whose Best Overall Response (BOR) was SD, per independent review committee (IRC) as the time between Week 12 and date of progressive disease (PD) or death , whichever occurs first. For those who underwent tumor resection following Week 12 but prior to PD, duration of SD was censored on date of last evaluable tumor assessment (TA) prior to resection. For those with BOR of SD at Week 12, date of PD was used in analysis of duration of SD. For those with BOR=SD who have not subsequently progressed and who remain alive, duration of SD censored on date of last evaluable TA. Modified criteria of the World Health Organization (mWHO): SD=insufficient decrease to qualify for partial response or sufficient increase to qualify for PD; PD=an increase of 25% or more in sum of products of longest diameter and greatest perpendicular diameter of index lesions compared with smallest recorded sum, or appearance of 1 or more new lesions.
Week 12 to date of disease progression or death up to data cutoff for primary endpoint (approximately 5 years)
Percentage of Participants With Brain Metastasis-Free Survival at Time of Data Cutoff
기간: Date of randomization up to data cutoff for primary endpoint (approximately 5 years)
Brain metastasis-free survival was defined as the time from randomization to the date of progression with a new lesion located in the brain. New brain lesions prior to Week 12 constituted a progression event (unlike main progression-free survival analysis). A participant who dies without documentation of a brain lesion was considered to have progressed with brain metastasis on the date of death. Participants who are free of brain metastasis were censored on the date of their last tumor assessment. An independent review committee evaluated images of participants with clinical symptoms to determine the number of those free of brain metastasis. The brain metastasis-free status was reported as a percent of participants (n/N), where n= participants with metastasis-free brains at data cutoff for the Primary Endpoint and N= randomized participants. A 2-sided Clopper and Pearson confidence interval was performed.
Date of randomization up to data cutoff for primary endpoint (approximately 5 years)
Number of Participants With Adverse Events (AEs), Drug-related AEs, AEs Leading to Discontinuation, Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related Hypersensitivity, Immune-related AEs/SAEs, and Inflammatory AEs/SAEs
기간: Week 1 (First Dose) to 70 days after last dose of study up to data cutoff for primary endpoint (approximately 5 years)
AE=any new undesirable symptom, sign, clinically significant laboratory abnormality, or medical condition occurring after starting study treatment, even if the event was not considered to be drug-related. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4= Potentially Life-threatening or disabling. Randomization=Day 1; start of treatment (first dose)=Week 1. Summarization time frame is from first dose to 70 days after last dose of study at time of 414 deaths.
Week 1 (First Dose) to 70 days after last dose of study up to data cutoff for primary endpoint (approximately 5 years)
Number of Participants With Grade 2-3 and Grade 3-4 Immune-related Adverse Events (irAEs) With Resolution Resolved
기간: Week 1 (first dose) to 70 days after last dose up to data cutoff for primary endpoint (approximately 5 years)
irAEs included the categories: gastrointestinal (GI), diarrhea, liver, endocrine, and skin. Grade 2=moderate adverse events (AEs); minimal, local, or noninvasive intervention indicated. Grade 3=severe AEs, medically significant but not immediately life-threatening. Grade 4=life-threatening consequences; urgent intervention indicated. Resolution is defined as improvement to Grade 1 or less or to the Grade at baseline (prior to treatment).
Week 1 (first dose) to 70 days after last dose up to data cutoff for primary endpoint (approximately 5 years)
Time to Resolution of Grade 2-3, Grade 3-4 Immune-related Adverse Events (irAEs)
기간: Week 1 (first dose) to 70 days after last dose up to database lock for primary endpoint (approximately 5 years)
irAEs included the categories: gastrointestinal (GI), diarrhea, liver, endocrine, and skin. Grade 2=Moderate adverse events (AEs); minimal, local or noninvasive intervention indicated. Grade 3=severe AEs, medically significant but not immediately life-threatening. Grade 4=life-threatening consequences; urgent intervention indicated. Time to resolution is defined as improvement to Grade 1 or less or to the Grade at baseline (prior to treatment).
Week 1 (first dose) to 70 days after last dose up to database lock for primary endpoint (approximately 5 years)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Bristol-Myers Squibb

협력자

Medarex

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2006년 8월 1일

기본 완료 (실제)

2011년 1월 1일

연구 완료 (실제)

2013년 10월 1일

연구 등록 날짜

최초 제출

2006년 5월 8일

QC 기준을 충족하는 최초 제출

2006년 5월 9일

처음 게시됨 (추정)

2006년 5월 10일

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

2014년 11월 2일

QC 기준을 충족하는 마지막 업데이트 제출

2014년 10월 24일

마지막으로 확인됨

2014년 10월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • CA184-024

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

Ipilimumab에 대한 임상 시험

유사한 임상시험 검색

스폰서 및 공동 작업자

건강 상태

약물 개입

CROs by country

CROs in Russia

정황

희귀 질병

약물 개입

식이 보충제

스폰서 / 협력자

위치

구독하다